These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35491563)
1. The making of the one pill-Developing single tablet regimens for HIV and for HCV. Yang T; Oliyai R; Kent KM Antivir Ther; 2022 Apr; 27(2):13596535211067606. PubMed ID: 35491563 [TBL] [Abstract][Full Text] [Related]
2. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Deeks ED; Perry CM Drugs; 2010 Dec; 70(17):2315-38. PubMed ID: 21080746 [TBL] [Abstract][Full Text] [Related]
3. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. Lyseng-Williamson KA; Scott LJ Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088 [TBL] [Abstract][Full Text] [Related]
4. The transformation of HIV therapy: One pill once a day. Choudhary MC; Mellors JW Antivir Ther; 2022 Apr; 27(2):13596535211062396. PubMed ID: 35492017 [TBL] [Abstract][Full Text] [Related]
5. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057 [TBL] [Abstract][Full Text] [Related]
8. Single-tablet regimens in HIV: does it really make a difference? Aldir I; Horta A; Serrado M Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862 [TBL] [Abstract][Full Text] [Related]
9. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Olin JL; Spooner LM; Klibanov OM Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357 [TBL] [Abstract][Full Text] [Related]
10. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Mocroft A; Reiss P; Rakhmanova A; Banhegyi D; Phillips AN; De Wit S; Ristola M; Lundgren JD; Grarup J; Kirk O; Infection; 2014 Aug; 42(4):757-62. PubMed ID: 24902520 [TBL] [Abstract][Full Text] [Related]
11. Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment. Manzardo C; Gatell JM AIDS Rev; 2014; 16(1):35-42. PubMed ID: 24584107 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045 [TBL] [Abstract][Full Text] [Related]
13. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet. Marchand C Expert Opin Investig Drugs; 2012 Jul; 21(7):901-4. PubMed ID: 22571404 [TBL] [Abstract][Full Text] [Related]
14. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A; J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529 [TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J; J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460 [TBL] [Abstract][Full Text] [Related]
16. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Goicoechea M; Best B Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471 [TBL] [Abstract][Full Text] [Related]
17. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918 [TBL] [Abstract][Full Text] [Related]
18. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Perry CM Drugs; 2009; 69(7):843-57. PubMed ID: 19441871 [TBL] [Abstract][Full Text] [Related]
19. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral rounds. Is that "one pill" treatment enough? Gallant JE; Arribas JR AIDS Clin Care; 2008 Jul; 20(7):53-4. PubMed ID: 18724479 [No Abstract] [Full Text] [Related] [Next] [New Search]